RANK Receptor, soluble Active Protein | RANK Receptor active protein

Human RANK Receptor, soluble

Cat. Num. AAA691486

• Gene Names: TNFRSF11A; FEO; OFE; ODFR; OSTS; PDB2; RANK; CD265; OPTB7; TRANCER; LOH18CR1
• Reactivity: Human
• Purity: > 98% (SDS-PAGE, HPLC)
• Synonyms: RANK Receptor; soluble; Human RANK Receptor; Recombinant Human sRANK Ligand (sRANKL); RANK Receptor active protein

• Host: E Coli
• Reactivity: Human
• Purity/Purification: > 98% (SDS-PAGE, HPLC)
• Form/Format: Lyophilized
• Sequence: MQIAPPCTSE KHYEHLGRCC NKCEPGKYMS SKCTTTSDSV CLPCGP DEYL DSWNEEDKCL LHKVCDTGKA LVAVVAGNST TPRRCACTAG Y HWSQDCECC RRNTECAPGL GAQHPLQLNK DTVCKPCLAG YFSDAFS STD KCRPWTNCTF LGKRVEHHGT EKSDAVCSSS LPARK
• Sequence Length: 299

• Endotoxin Level: < 0.1 ng per ug of sRANKL
• Biological Activity: Determined by its ability to inhibit sRANKL induced NFkappaB in RAW264.7 cells in the absence of any cross-linking. The expected ED50 for this effect in the presence of 15ng/ml of recombinant sRANKL, is 30-50 ng/ml.

Related Product Information for RANK Receptor active protein

RANKL and RANK are members of the TNF superfamily of ligands and receptors that play an important role in the regulation of specific immunity and bone turnover. RANK (receptor) was originally identified as a dendritic-cell-membrane protein, which by interacting with RANKL augments the ability of dendritic cells to stimulate naive T cell proliferation and to promote the survival of RANK + T cells. RANK is also expressed in a variety of tissues including skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. The RANK/RANKL interaction is important in the regulation of osteoclastogenesis and in dendritic-cell-mediated T cell immune responses. Impairments in RANK signaling have been implicated in the induction of expansile osteolysis and Paget disease of bone (PDB2). Recombinant human sRANK receptor is a 19.3 kDa polypeptide containing the TNFR homologous cysteine rich portion of the extracellular domain of RANK receptor (175 amino acid residues).

Product Categories/Family for RANK Receptor active protein

Cytokines & Growth Factors

NCBI and Uniprot Product Information

• NCBI GI #: 401015109
• NCBI GeneID: 8792
• NCBI Accession #: NP_001257880.1
• NCBI GenBank Nucleotide #: NM_001270951.1
• UniProt Accession #: Q9Y6Q6; I4EC39
• Molecular Weight: 20.0 kDa
• NCBI Official Full Name: tumor necrosis factor receptor superfamily member 11A isoform 4
• NCBI Official Synonym Full Names: tumor necrosis factor receptor superfamily, member 11a, NFKB activator
• NCBI Official Symbol: TNFRSF11A
• NCBI Official Synonym Symbols: FEO; OFE; ODFR; OSTS; PDB2; RANK; CD265; OPTB7; TRANCER; LOH18CR1
• NCBI Protein Information: tumor necrosis factor receptor superfamily member 11A; Paget disease of bone 2; receptor activator of NF-KB; osteoclast differentiation factor receptor; receptor activator of nuclear factor-kappa B; loss of heterozygosity, 18, chromosomal region 1
• UniProt Protein Name: Tumor necrosis factor receptor superfamily member 11A
• UniProt Gene Name: TNFRSF11A
• UniProt Synonym Gene Names: RANK; ODFR
• UniProt Entry Name: TNR11_HUMAN

NCBI Description

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptors can interact with various TRAF family proteins, through which this receptor induces the activation of NF-kappa B and MAPK8/JNK. This receptor and its ligand are important regulators of the interaction between T cells and dendritic cells. This receptor is also an essential mediator for osteoclast and lymph node development. Mutations at this locus have been associated with familial expansile osteolysis, autosomal recessive osteopetrosis, and Paget disease of bone. Alternatively spliced transcript variants have been described for this locus. [provided by RefSeq, Aug 2012]

Uniprot Description

Function: Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells. Ref.3

Subunit structure: Binds to the clefts between the subunits of the TNFSF11 ligand trimer to form a heterohexamer

By similarity. Interacts with TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6. Interacts (via cytoplasmic domain) with GAB2. Ref.4 Ref.5

Subcellular location: Membrane; Single-pass type I membrane protein

Potential.

Tissue specificity: Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland.

Involvement in disease: Familial expansile osteolysis (FEO) [MIM:174810]: Rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early-onset deafness and loss of dentition.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.7Paget disease of bone 2 (PDB2) [MIM:602080]: Bone-remodeling disorder with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.7Osteopetrosis, autosomal recessive 7 (OPTB7) [MIM:612301]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.8

Sequence similarities: Contains 4 TNFR-Cys repeats.